Primary neuroendocrine carcinoma of the breast

Chieh Sheng Lu, Shing Hwa Huang, Chiang Liang Ho, Jia Hong Chen, Tsu Yi Chao

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Primary neuroendocrine carcinoma of the breast (NECB) is a rare distinct type of breast carcinoma. There are only some case reports on this topic published in the past. There is still little known on the optimal treatment outcomes, while a wide variety of treatments is proposed by several authors. In this study we searched the literature on NECB in PubMed to clarify its prognosis and possible optimal therapeutic strategies. Methods: Eighty-six cases of primary NEC, included our case, were collected from PubMed between 1980 and 2013. Initial stage, estrogen receptor (ER/progesterone receptor (PR)/ human epidermal growth factor receptor 2 (HER-2), surgical procedures, adjuvant treatment and overall survive (OS) were analyzed using the Statistical Package for the Social Sciences (SPSS, v 16.0). Results: All 86 patients enrolled were eligible. Their mean age at diagnosis was 53.9 years (range 25-83) and 1 case was in a male. Overall survival (OS) at 48 months was 83.5%. Patients with enlarged tumor size (10 patients with tumor size >5.0 cm) or advanced stage (stage III 15 patients, stage IV 2 patients) had poor OS (48-month OS: 51.4 vs 97.1% with tumors >5cm vs

Original languageEnglish
Pages (from-to)419-429
Number of pages11
JournalJournal of B.U.ON.
Volume19
Issue number2
Publication statusPublished - 2014

Fingerprint

Neuroendocrine Carcinoma
Breast
PubMed
Neoplasms
Social Sciences
Progesterone Receptors
Estrogen Receptors
Therapeutics
Breast Neoplasms
Survival

Keywords

  • Breast
  • Estrogen receptor
  • Hormone therapy
  • Neuroendocrine carcinoma
  • Progesterone receptor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Radiology Nuclear Medicine and imaging

Cite this

Lu, C. S., Huang, S. H., Ho, C. L., Chen, J. H., & Chao, T. Y. (2014). Primary neuroendocrine carcinoma of the breast. Journal of B.U.ON., 19(2), 419-429.

Primary neuroendocrine carcinoma of the breast. / Lu, Chieh Sheng; Huang, Shing Hwa; Ho, Chiang Liang; Chen, Jia Hong; Chao, Tsu Yi.

In: Journal of B.U.ON., Vol. 19, No. 2, 2014, p. 419-429.

Research output: Contribution to journalArticle

Lu, CS, Huang, SH, Ho, CL, Chen, JH & Chao, TY 2014, 'Primary neuroendocrine carcinoma of the breast', Journal of B.U.ON., vol. 19, no. 2, pp. 419-429.
Lu CS, Huang SH, Ho CL, Chen JH, Chao TY. Primary neuroendocrine carcinoma of the breast. Journal of B.U.ON. 2014;19(2):419-429.
Lu, Chieh Sheng ; Huang, Shing Hwa ; Ho, Chiang Liang ; Chen, Jia Hong ; Chao, Tsu Yi. / Primary neuroendocrine carcinoma of the breast. In: Journal of B.U.ON. 2014 ; Vol. 19, No. 2. pp. 419-429.
@article{44c8790c6d6e4a44930a17026ee0bc54,
title = "Primary neuroendocrine carcinoma of the breast",
abstract = "Purpose: Primary neuroendocrine carcinoma of the breast (NECB) is a rare distinct type of breast carcinoma. There are only some case reports on this topic published in the past. There is still little known on the optimal treatment outcomes, while a wide variety of treatments is proposed by several authors. In this study we searched the literature on NECB in PubMed to clarify its prognosis and possible optimal therapeutic strategies. Methods: Eighty-six cases of primary NEC, included our case, were collected from PubMed between 1980 and 2013. Initial stage, estrogen receptor (ER/progesterone receptor (PR)/ human epidermal growth factor receptor 2 (HER-2), surgical procedures, adjuvant treatment and overall survive (OS) were analyzed using the Statistical Package for the Social Sciences (SPSS, v 16.0). Results: All 86 patients enrolled were eligible. Their mean age at diagnosis was 53.9 years (range 25-83) and 1 case was in a male. Overall survival (OS) at 48 months was 83.5{\%}. Patients with enlarged tumor size (10 patients with tumor size >5.0 cm) or advanced stage (stage III 15 patients, stage IV 2 patients) had poor OS (48-month OS: 51.4 vs 97.1{\%} with tumors >5cm vs",
keywords = "Breast, Estrogen receptor, Hormone therapy, Neuroendocrine carcinoma, Progesterone receptor",
author = "Lu, {Chieh Sheng} and Huang, {Shing Hwa} and Ho, {Chiang Liang} and Chen, {Jia Hong} and Chao, {Tsu Yi}",
year = "2014",
language = "English",
volume = "19",
pages = "419--429",
journal = "Journal of B.U.ON.",
issn = "1107-0625",
publisher = "Balkan Union of Oncology",
number = "2",

}

TY - JOUR

T1 - Primary neuroendocrine carcinoma of the breast

AU - Lu, Chieh Sheng

AU - Huang, Shing Hwa

AU - Ho, Chiang Liang

AU - Chen, Jia Hong

AU - Chao, Tsu Yi

PY - 2014

Y1 - 2014

N2 - Purpose: Primary neuroendocrine carcinoma of the breast (NECB) is a rare distinct type of breast carcinoma. There are only some case reports on this topic published in the past. There is still little known on the optimal treatment outcomes, while a wide variety of treatments is proposed by several authors. In this study we searched the literature on NECB in PubMed to clarify its prognosis and possible optimal therapeutic strategies. Methods: Eighty-six cases of primary NEC, included our case, were collected from PubMed between 1980 and 2013. Initial stage, estrogen receptor (ER/progesterone receptor (PR)/ human epidermal growth factor receptor 2 (HER-2), surgical procedures, adjuvant treatment and overall survive (OS) were analyzed using the Statistical Package for the Social Sciences (SPSS, v 16.0). Results: All 86 patients enrolled were eligible. Their mean age at diagnosis was 53.9 years (range 25-83) and 1 case was in a male. Overall survival (OS) at 48 months was 83.5%. Patients with enlarged tumor size (10 patients with tumor size >5.0 cm) or advanced stage (stage III 15 patients, stage IV 2 patients) had poor OS (48-month OS: 51.4 vs 97.1% with tumors >5cm vs

AB - Purpose: Primary neuroendocrine carcinoma of the breast (NECB) is a rare distinct type of breast carcinoma. There are only some case reports on this topic published in the past. There is still little known on the optimal treatment outcomes, while a wide variety of treatments is proposed by several authors. In this study we searched the literature on NECB in PubMed to clarify its prognosis and possible optimal therapeutic strategies. Methods: Eighty-six cases of primary NEC, included our case, were collected from PubMed between 1980 and 2013. Initial stage, estrogen receptor (ER/progesterone receptor (PR)/ human epidermal growth factor receptor 2 (HER-2), surgical procedures, adjuvant treatment and overall survive (OS) were analyzed using the Statistical Package for the Social Sciences (SPSS, v 16.0). Results: All 86 patients enrolled were eligible. Their mean age at diagnosis was 53.9 years (range 25-83) and 1 case was in a male. Overall survival (OS) at 48 months was 83.5%. Patients with enlarged tumor size (10 patients with tumor size >5.0 cm) or advanced stage (stage III 15 patients, stage IV 2 patients) had poor OS (48-month OS: 51.4 vs 97.1% with tumors >5cm vs

KW - Breast

KW - Estrogen receptor

KW - Hormone therapy

KW - Neuroendocrine carcinoma

KW - Progesterone receptor

UR - http://www.scopus.com/inward/record.url?scp=84904187384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904187384&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 419

EP - 429

JO - Journal of B.U.ON.

JF - Journal of B.U.ON.

SN - 1107-0625

IS - 2

ER -